MedTrace Logo

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 542

Last updated 2017-04-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.

Conditions

Interventions

DRUG

AZD6765 iv

50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.

DRUG

AZD6765 iv

100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.

DRUG

Placebo

0.9 sodium chloride \[normal saline\] solution for injection by iv infusion

Sponsors & Collaborators

Principal Investigators

  • Dhaval A Desai, MD · 1800 Concord Pike, Wilmington, DE 19850

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-16
Primary Completion
2013-08-26
Completion
2013-08-26

Countries

  • United States
  • Chile
  • Slovakia
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01482221 on ClinicalTrials.gov